IRIS Accounts Production v23.4.0.336 14281592 Board of Directors 8.8.22 31.8.23 31.8.23 false true false false true false Ordinary 0.01000 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh142815922022-08-07142815922023-08-31142815922022-08-082023-08-31142815922022-08-0714281592ns15:EnglandWales2022-08-082023-08-3114281592ns14:PoundSterling2022-08-082023-08-3114281592ns10:Director12022-08-082023-08-3114281592ns10:PrivateLimitedCompanyLtd2022-08-082023-08-3114281592ns10:SmallEntities2022-08-082023-08-3114281592ns10:AuditExempt-NoAccountantsReport2022-08-082023-08-3114281592ns10:SmallCompaniesRegimeForDirectorsReport2022-08-082023-08-3114281592ns10:SmallCompaniesRegimeForAccounts2022-08-082023-08-3114281592ns10:FullAccounts2022-08-082023-08-3114281592ns10:OrdinaryShareClass12022-08-082023-08-3114281592ns10:OrdinaryShareClass1112022-08-082023-08-3114281592ns10:Director22022-08-082023-08-3114281592ns10:Director32022-08-082023-08-3114281592ns10:RegisteredOffice2022-08-082023-08-3114281592ns5:CurrentFinancialInstruments2023-08-3114281592ns5:ShareCapital2023-08-3114281592ns5:SharePremium2023-08-3114281592ns5:RetainedEarningsAccumulatedLosses2023-08-3114281592ns5:PlantMachinery2022-08-082023-08-3114281592ns5:ComputerEquipment2022-08-082023-08-3114281592ns5:PlantMachinery2023-08-3114281592ns5:ComputerEquipment2023-08-3114281592ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-08-3114281592ns5:Non-currentFinancialInstruments2023-08-3114281592ns10:OrdinaryShareClass12023-08-311428159212022-08-082023-08-31
REGISTERED NUMBER: 14281592 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023

FOR

LONDON LABORATORY LTD

LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023










Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


LONDON LABORATORY LTD

COMPANY INFORMATION
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023







DIRECTORS: Mr D Smith
Prof. A J Wilson
Mr S J Checkley





REGISTERED OFFICE: Unit 2.02 High Weald House
Glovers End
Bexhill
East Sussex
TN39 5ES





REGISTERED NUMBER: 14281592 (England and Wales)





ACCOUNTANTS: Acuity Professional Partnership LLP
Business Advisers and Accountants
Unit 2.02 High Weald House,
Glovers End
Bexhill
East Sussex
United Kingdom
TN39 5ES

LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

STATEMENT OF FINANCIAL POSITION
31 AUGUST 2023

Notes £    £   
FIXED ASSETS
Tangible assets 4 151,779

CURRENT ASSETS
Stocks 5 95,207
Debtors 6 250,640
Cash at bank 1,217
347,064
CREDITORS
Amounts falling due within one year 7 1,021,138
NET CURRENT LIABILITIES (674,074 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(522,295

)

CAPITAL AND RESERVES
Called up share capital 8 10
Share premium 99,990
Retained Losses (622,295 )
SHAREHOLDERS' FUNDS (522,295 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 August 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 August 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21 February 2024 and were signed on its behalf by:



Mr S J Checkley - Director


LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023


1. STATUTORY INFORMATION

London Laboratory Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

SIGNIFICANT JUDGEMENTS AND ESTIMATES
In preparing the financial statements, the directors are required to make estimates and judgments about thecarrying amounts of assets and liabilities. The estimates and assumptions are reviewed on an ongoing basis andare based on historical experience and other factors that are considered by the directors to be relevant. Revision to accounting estimates are recognised in the period in which the estimate is revised.

TURNOVER
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance
Computer equipment - 25% on reducing balance

STOCKS
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023


2. ACCOUNTING POLICIES - continued

FINANCIAL INSTRUMENTS
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.
Financial instruments are recognized in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognized amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortized cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortized.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans and loans from fellow group companies that are classified as debt, are initially recognized at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payment discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortized.

Debt instruments are subsequently carried at amortized cost, using the effective interest rate method.

TAXATION
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

DEFERRED TAX
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023


2. ACCOUNTING POLICIES - continued

GOING CONCERN
The company's balance sheet shows net deficit shareholders fund position at the end of the period. However, the directors have received confirmation from the shareholders of their continued financial support for the foreseeable future.and for at least twelve months from the date of signature of these accounts.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 10 .

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
Cost
Additions 164,370 1,924 166,294
At 31 August 2023 164,370 1,924 166,294
Depreciation
Charge for period 14,377 138 14,515
At 31 August 2023 14,377 138 14,515
Net book value
At 31 August 2023 149,993 1,786 151,779

5. STOCKS
£   
Stocks 95,207

6. DEBTORS
£   
Amounts falling due within one year:
Trade debtors 6,580
Other debtors 36,830
43,410

Amounts falling due after more than one year:
Deferred tax asset 207,230

Aggregate amounts 250,640

LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023


7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Social security 80,306
Trade creditors 451,887
Amounts owed to group undertakings 466,563
Other creditors 22,382
1,021,138

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal
value: £   
1,040 Ordinary £.01 10

1,040 Ordinary shares of £.01 each were allotted as fully paid at a premium of £96.1438 per share during the period.

9. POST BALANCE SHEET EVENTS

Subsequent to the reporting date but before the approval of these financial statements, there has been a significant change in the ownership structure of the Company. As at 06 September 2023, Jorja Healthcare Holdings Ltd has acquired 100% share capital of the Company.
This change in shareholding occurred after the balance sheet date but is deemed to be a non-adjusting event. The impact of this change on the financial position and results of operations is not reflected in these financial statements.